LLY

1,121.73

-0.42%↓

JNJ

234.77

-0.59%↓

ABBV

221.66

+0.03%↑

UNH

408.3

-1.05%↓

MRK

115.04

-0.36%↓

LLY

1,121.73

-0.42%↓

JNJ

234.77

-0.59%↓

ABBV

221.66

+0.03%↑

UNH

408.3

-1.05%↓

MRK

115.04

-0.36%↓

LLY

1,121.73

-0.42%↓

JNJ

234.77

-0.59%↓

ABBV

221.66

+0.03%↑

UNH

408.3

-1.05%↓

MRK

115.04

-0.36%↓

LLY

1,121.73

-0.42%↓

JNJ

234.77

-0.59%↓

ABBV

221.66

+0.03%↑

UNH

408.3

-1.05%↓

MRK

115.04

-0.36%↓

LLY

1,121.73

-0.42%↓

JNJ

234.77

-0.59%↓

ABBV

221.66

+0.03%↑

UNH

408.3

-1.05%↓

MRK

115.04

-0.36%↓

Search

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

503.88 2.82

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

488.93

Max

506.47

Belangrijke statistieken

By Trading Economics

Inkomsten

-36M

-94M

Verkoop

-9.7M

311M

EPS

-1.38

Winstmarge

-30.318

Werknemers

915

EBITDA

-43M

-93M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+34.95% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.2B

11B

Vorige openingsprijs

501.06

Vorige sluitingsprijs

503.88

Nieuwssentiment

By Acuity

47%

53%

153 / 342 Rangschikking in Healthcare

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
help-icon Live chat